GeneDx (NASDAQ:WGS) Director Casdin Capital, Llc Purchases 150,000 Shares

GeneDx Holdings Corp. (NASDAQ:WGS) Director Casdin Capital, Llc acquired 150,000 shares of GeneDx stock in a transaction that occurred on Thursday, June 4th. The shares were bought at an average price of $56.44 per share, with a total value of $8,466,000.00. Following the transaction, the director directly owned 3,657,164 shares in the company, valued at approximately $206,410,336.16. This trade represents a 4.28% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Casdin Capital, Llc also recently made the following trade(s):

• On Friday, June 5th, Casdin Capital, Llc acquired 50,000 shares of GeneDx stock. The shares were bought at an average price of $52.86 per share, with a total value of $2,643,000.00.
• On Wednesday, May 20th, Casdin Capital, Llc acquired 140,000 shares of GeneDx stock. The shares were bought at an average price of $43.81 per share, with a total value of $6,133,400.00.
• On Tuesday, May 19th, Casdin Capital, Llc acquired 185,000 shares of GeneDx stock. The shares were bought at an average price of $42.60 per share, with a total value of $7,881,000.00.
• On Monday, May 18th, Casdin Capital, Llc acquired 175,000 shares of GeneDx stock. The shares were bought at an average price of $42.55 per share, with a total value of $7,446,250.00.

GeneDx Stock Down 0.8%

Shares of GeneDx stock opened at $51.80 on Tuesday. The business’s fifty day moving average price is $55.25 and its two-hundred day moving average price is $92.12. The company has a debt-to-equity ratio of 0.38, a current ratio of 3.09 and a quick ratio of 2.95. The company has a market capitalization of $1.54 billion, a P/E ratio of -19.33 and a beta of 1.96. GeneDx Holdings Corp. has a 1-year low of $32.21 and a 1-year high of $170.87.

GeneDx (NASDAQ:WGS) last announced its earnings results on Monday, May 4th. The company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.22). The business had revenue of $102.25 million for the quarter, compared to the consensus estimate of $112.46 million. GeneDx had a negative net margin of 17.58% and a positive return on equity of 9.15%. During the same period in the previous year, the firm earned ($0.23) EPS. As a group, research analysts forecast that GeneDx Holdings Corp. will post -1 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on WGS. Wells Fargo & Company reaffirmed an “overweight” rating and set a $75.00 target price (down from $155.00) on shares of GeneDx in a research note on Tuesday, May 5th. BTIG Research dropped their price objective on GeneDx from $170.00 to $90.00 and set a “buy” rating on the stock in a research note on Tuesday, May 5th. Jefferies Financial Group set a $150.00 price objective on GeneDx in a research note on Monday, February 23rd. Craig Hallum reissued a “buy” rating and issued a $85.00 price objective on shares of GeneDx in a research note on Tuesday, May 5th. Finally, Weiss Ratings downgraded GeneDx from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday, June 1st. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $96.43.

Key Headlines Impacting GeneDx

Here are the key news stories impacting GeneDx this week:

• Positive Sentiment: Director Casdin Capital bought 150,000 shares at an average price of $56.44, a sizable insider purchase that may signal management/board confidence in GeneDx’s long-term outlook. SEC filing
• Positive Sentiment: Casdin Capital also reported another purchase of 50,000 shares at $52.86, reinforcing the recent insider accumulation trend. SEC filing
• Neutral Sentiment: Analyst coverage remains constructive overall, with GeneDx receiving an average rating of “Moderate Buy,” which may help support the stock over time. Analyst rating update
• Negative Sentiment: Multiple law firms announced or reminded investors about a securities class-action lawsuit against GeneDx, increasing legal overhang and uncertainty for shareholders. Class action announcement
• Negative Sentiment: The litigation centers on alleged investor harm tied to GeneDx’s prior disclosures and a sharp post-earnings selloff, keeping attention on operational and disclosure risks. Litigation article

Institutional Trading of GeneDx

A number of hedge funds and other institutional investors have recently modified their holdings of WGS. Westfield Capital Management Co. LP raised its stake in shares of GeneDx by 87.1% in the 4th quarter. Westfield Capital Management Co. LP now owns 1,018,261 shares of the company’s stock worth $132,435,000 after buying an additional 474,167 shares in the last quarter. ARK Investment Management LLC acquired a new stake in shares of GeneDx during the third quarter worth $48,157,000. Franklin Resources Inc. raised its position in shares of GeneDx by 60.4% during the fourth quarter. Franklin Resources Inc. now owns 1,092,988 shares of the company’s stock worth $142,154,000 after purchasing an additional 411,607 shares during the period. Invesco Ltd. raised its position in shares of GeneDx by 59.2% during the fourth quarter. Invesco Ltd. now owns 786,466 shares of the company’s stock worth $102,288,000 after purchasing an additional 292,394 shares during the period. Finally, Amova Asset Management Americas Inc. acquired a new stake in shares of GeneDx during the third quarter worth $31,444,000. Institutional investors own 61.72% of the company’s stock.

GeneDx Company Profile

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.